Affiliation:
1. College of Medicine, Jabir bin Hayyan Medical University, Najaf, Iraq
2. University of Kufa, College of science, Najaf, Iraq
Abstract
Abstract
Objectives:
The present study aims to explain the vital role of scavenger receptor class B type I (SR-B1) expression in aggressive and developed prostatic cancer.
Materials and Methods:
One hundred eighty males were enrolled in this study between December 2021 and June 2022. They were divided into four groups. The first group served as a control group. The second group included the newly diagnosed patients with malignant prostate cancer. The third group involved the patients who received treatment, and the last group involved those with benign prostate hyperplasia. Prostate cancer patients were divided into three stages and grades (scores). The stages are Ⅱ, Ⅲ, and ΙⅤ, and the scores are 5, 6, and 7, 8, 9, respectively. We studied SR-B1 in the serum of suspected patients.
Results:
The results revealed a significant increase in SR-B1 in prostate cancer patients compared to benign, tumor-treated, and control groups. They also demonstrated a substantial increase in SR-B1 in the subgroup with age range 50–59 years, in comparison with 60–69 years in all patient groups. In addition, SR-B1 recorded a significant increase in both new diagnosed and tumor-treated patients at grade IV compared to grades III and II and grades 7, 8, and 9 compared to grades 5 and 6 in both newly diagnosed and tumor-treated patients.
Conclusion:
This study showed that SR-B1 has an important role in aggressiveness and development of prostate cancer, with the possibility of using this marker for initial detection of cancer.